[go: up one dir, main page]

UA110806C2 - Мікобактеріальна антигенна композиція - Google Patents

Мікобактеріальна антигенна композиція

Info

Publication number
UA110806C2
UA110806C2 UAA201306356A UAA201306356A UA110806C2 UA 110806 C2 UA110806 C2 UA 110806C2 UA A201306356 A UAA201306356 A UA A201306356A UA A201306356 A UAA201306356 A UA A201306356A UA 110806 C2 UA110806 C2 UA 110806C2
Authority
UA
Ukraine
Prior art keywords
antigenic composition
mycobacterial antigenic
sequence
composition
seq
Prior art date
Application number
UAA201306356A
Other languages
English (en)
Russian (ru)
Inventor
Стефан Андре Ґеорґес Ґодарт
Аміна Ланан
Домінік Інґрід Лемоін
Original Assignee
Ґлаксосмітклайн Байолоджікалз С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ґлаксосмітклайн Байолоджікалз С.А. filed Critical Ґлаксосмітклайн Байолоджікалз С.А.
Publication of UA110806C2 publication Critical patent/UA110806C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

Винахід стосується імуногенної композиції, яка містить антиген, споріднений з Rv1196, де антиген, споріднений з Rv1196, включає (а) послідовність, що має принаймні 90 % ідентичності з послідовністю SEQ ID No: 1 або (b) фрагмент послідовності SEQ ID No: 1, який містить принаймні 350 амінокислот у довжину, та де електропровідність композиції складає 5 мСм/см або менше, а рН вказаної композиції лежить в інтервалі від 7,0, до 9,0.
UAA201306356A 2010-12-14 2011-12-14 Мікобактеріальна антигенна композиція UA110806C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42272310P 2010-12-14 2010-12-14
PCT/EP2011/072817 WO2012080370A1 (en) 2010-12-14 2011-12-14 Mycobacterium antigenic composition

Publications (1)

Publication Number Publication Date
UA110806C2 true UA110806C2 (uk) 2016-02-25

Family

ID=45346501

Family Applications (2)

Application Number Title Priority Date Filing Date
UAA201306356A UA110806C2 (uk) 2010-12-14 2011-12-14 Мікобактеріальна антигенна композиція
UAA201306355A UA110118C2 (uk) 2010-12-14 2011-12-14 Мікобактеріальна антигенна композиція

Family Applications After (1)

Application Number Title Priority Date Filing Date
UAA201306355A UA110118C2 (uk) 2010-12-14 2011-12-14 Мікобактеріальна антигенна композиція

Country Status (33)

Country Link
US (5) US9352030B2 (uk)
EP (4) EP3593813A1 (uk)
JP (2) JP5951633B2 (uk)
KR (3) KR101951894B1 (uk)
CN (4) CN106822882A (uk)
AR (1) AR084285A1 (uk)
AU (2) AU2011343367B2 (uk)
BR (2) BR112013014598A2 (uk)
CA (2) CA2819298A1 (uk)
CO (2) CO6751288A2 (uk)
CY (1) CY1122187T1 (uk)
DK (3) DK3023106T3 (uk)
EA (2) EA027920B1 (uk)
ES (3) ES2567190T3 (uk)
HR (3) HRP20160606T1 (uk)
HU (3) HUE027932T2 (uk)
IL (2) IL226448A (uk)
LT (1) LT3023106T (uk)
ME (1) ME02380B (uk)
MX (2) MX344706B (uk)
MY (1) MY161412A (uk)
PH (2) PH12013501204A1 (uk)
PL (3) PL3023106T3 (uk)
PT (2) PT3023106T (uk)
RS (1) RS54687B1 (uk)
SG (2) SG190937A1 (uk)
SI (3) SI2651436T1 (uk)
SM (1) SMT201600118B (uk)
TW (1) TW201305192A (uk)
UA (2) UA110806C2 (uk)
UY (1) UY33802A (uk)
WO (2) WO2012080369A1 (uk)
ZA (2) ZA201304014B (uk)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006243357B2 (en) 2005-04-29 2012-03-15 Glaxosmithkline Biologicals S.A. Novel method for preventing or treating M tuberculosis infection
UA110806C2 (uk) 2010-12-14 2016-02-25 Ґлаксосмітклайн Байолоджікалз С.А. Мікобактеріальна антигенна композиція
EP2661253B1 (en) * 2011-01-04 2017-04-19 Archivel Farma, SL Liposome formulation suitable for treating or preventing tuberculosis
WO2013104943A1 (en) 2012-01-12 2013-07-18 Archivel Farma, S.L. Mtb-c vaccine against asthma
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
WO2015164675A1 (en) 2014-04-23 2015-10-29 Juno Therapeutics, Inc. Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy
GB201513176D0 (en) * 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
GB201522068D0 (en) * 2015-12-15 2016-01-27 Glaxosmithkline Biolog Sa Dried composition
BE1025160B1 (fr) 2016-12-07 2018-11-26 Glaxosmithkline Biologicals Sa Nouveau procédé
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
GB201707700D0 (en) 2017-05-12 2017-06-28 Glaxosmithkline Biologicals Sa Dried composition
GB2600652B (en) 2017-05-30 2022-11-02 Glaxosmithkline Biologicals Sa Novel compositions
EP3717001A1 (en) 2017-12-01 2020-10-07 GlaxoSmithKline Biologicals S.A. Saponin purification
RU2728976C2 (ru) * 2018-03-22 2020-08-03 Зули Холдингз, Лтд. Липосомный состав и его получение
US20210292395A1 (en) 2018-07-31 2021-09-23 Glaxosmithkline Biologicals Sa Antigen purification method
WO2020109365A1 (en) 2018-11-29 2020-06-04 Glaxosmithkline Biologicals Sa Methods for manufacturing an adjuvant
JP7640473B2 (ja) 2019-06-05 2025-03-05 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム サポニン精製
EP3777884A1 (en) 2019-08-15 2021-02-17 GlaxoSmithKline Biologicals S.A. Immunogenic composition
CN114466659A (zh) 2019-09-09 2022-05-10 葛兰素史克生物有限公司 免疫治疗组合物
WO2021099982A1 (en) 2019-11-22 2021-05-27 Glaxosmithkline Biologicals Sa Dosage and administration of a bacterial saccharide glycoconjugate vaccine
WO2021224205A1 (en) 2020-05-05 2021-11-11 Glaxosmithkline Biologicals Sa Microfluidic mixing device and methods of use
US20230234992A1 (en) 2020-06-05 2023-07-27 Glaxosmithkline Biologicals Sa Modified betacoronavirus spike proteins
EP4259814A2 (en) 2020-12-09 2023-10-18 GlaxoSmithKline Biologicals SA Modification of saponins
CN114034860A (zh) * 2021-11-01 2022-02-11 宁夏大学 一种结核分枝杆菌mtb39a蛋白抗体间接elisa检测方法及其试剂盒
WO2023242187A1 (en) 2022-06-15 2023-12-21 Glaxosmithkline Biologicals Sa Enzymatic modification of saponins
CN116120411B (zh) * 2022-12-07 2024-04-12 中国疾病预防控制中心传染病预防控制所 结核分枝杆菌蛋白抗原混合物、多抗原融合蛋白及编码基因和应用

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436727A (en) 1982-05-26 1984-03-13 Ribi Immunochem Research, Inc. Refined detoxified endotoxin product
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4877611A (en) 1986-04-15 1989-10-31 Ribi Immunochem Research Inc. Vaccine containing tumor antigens and adjuvants
CA1331443C (en) 1987-05-29 1994-08-16 Charlotte A. Kensil Saponin adjuvant
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
EP0382271B1 (en) 1989-02-04 1994-12-21 Akzo Nobel N.V. Tocols as adjuvant in vaccine
ATE204762T1 (de) 1993-03-23 2001-09-15 Smithkline Beecham Biolog 3-0-deazylierte monophosphoryl lipid a enthaltende impfstoff-zusammensetzungen
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
ES2366201T3 (es) 1994-07-15 2011-10-18 University Of Iowa Research Foundation Oligonucleótidos inmunmoduladores.
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DK2154248T3 (da) 1995-09-01 2012-01-30 Corixa Corp Forbindelser og fremgangsmåder til diagnose af tuberkulose
ATE323165T1 (de) 1995-09-01 2006-04-15 Corixa Corp Verbindungen und verfahren zur immuntherapie und diagnose von tuberkulose
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
GB9619613D0 (en) 1996-09-19 1996-10-30 Breed Automotive Tech An inflatable restraint for a vehicle
EP0859366A1 (en) 1997-02-12 1998-08-19 STMicroelectronics S.r.l. Associative memory device with optimized occupation, particularly for the recognition of words
ATE261734T1 (de) * 1997-04-08 2004-04-15 Merck & Co Inc Stabilisierte humane papillomaviruszusammensetzungen
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
DE19803453A1 (de) * 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
KR100692227B1 (ko) * 1998-04-07 2007-03-09 코릭사 코포레이션 마이코박테리움 튜베르쿨로시스 항원의 융합 단백질 및이의 용도
JP2002511423A (ja) * 1998-04-09 2002-04-16 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ワクチン
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US20040006242A1 (en) 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US7311922B1 (en) 1999-10-07 2007-12-25 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
PT1542732E (pt) 2000-06-20 2009-11-06 Corixa Corp Proteínas de fusão de mycobacterium tuberculosis
MXPA03000198A (es) 2000-06-29 2004-09-13 Glaxosmithkline Biolog Sa Composicion de vacuna multivalente.
WO2003070187A2 (en) 2002-02-15 2003-08-28 Corixa Corporation Fusion proteins of mycobacterium tuberculosis
GB0411411D0 (en) 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
AU2006243357B2 (en) 2005-04-29 2012-03-15 Glaxosmithkline Biologicals S.A. Novel method for preventing or treating M tuberculosis infection
EP2087128A4 (en) * 2006-11-01 2009-11-04 Immport Therapeutics Inc COMPOSITIONS AND METHODS FOR IMMUNOMINANT ANTIGENES
WO2008142133A1 (en) 2007-05-24 2008-11-27 Glaxosmithkline Biologicals S.A Lyophilised antigen composition
CN104645329A (zh) * 2007-11-30 2015-05-27 Abbvie公司 蛋白制剂及其制备方法
KR100955470B1 (ko) * 2008-01-09 2010-04-30 대한민국(관리부서 질병관리본부장) 탄저 방어 항원의 제조 방법
US8409901B2 (en) 2008-03-11 2013-04-02 The Royal Institution For The Advancement Of Learning/Mcgill University Low temperature wafer level processing for MEMS devices
GB0910045D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB201008512D0 (en) 2010-05-21 2010-07-07 Health Prot Agency Mycobacterial antigen composition
IT1400834B1 (it) 2010-07-07 2013-07-02 Aero Sekur S P A Metodo e sistema per l'atterraggio di emergenza di un veicolo, come un elicottero o simili.
UA110806C2 (uk) 2010-12-14 2016-02-25 Ґлаксосмітклайн Байолоджікалз С.А. Мікобактеріальна антигенна композиція
GB201400819D0 (en) 2014-01-17 2014-03-05 Sec Dep For Health The Mycobacterial antigen composition

Also Published As

Publication number Publication date
CA2819297A1 (en) 2012-06-21
KR20190022897A (ko) 2019-03-06
AU2011343368B2 (en) 2015-08-20
WO2012080369A1 (en) 2012-06-21
AU2011343367A1 (en) 2013-07-11
CN103249431A (zh) 2013-08-14
SI2651437T1 (sl) 2016-05-31
JP2014505036A (ja) 2014-02-27
CN103260642A (zh) 2013-08-21
MX2013006818A (es) 2013-08-26
EP3023106B1 (en) 2019-07-31
CO6751288A2 (es) 2013-09-16
HUE027932T2 (en) 2016-11-28
PL2651436T3 (pl) 2016-10-31
SI3023106T1 (sl) 2019-11-29
DK2651437T3 (en) 2016-05-02
US20190183998A1 (en) 2019-06-20
RS54687B1 (sr) 2016-08-31
HRP20160362T1 (hr) 2016-05-06
HUE045766T2 (hu) 2020-01-28
US9352030B2 (en) 2016-05-31
JP2013545783A (ja) 2013-12-26
US20130280289A1 (en) 2013-10-24
US20180071378A1 (en) 2018-03-15
CN106822883A (zh) 2017-06-13
EA201390631A1 (ru) 2014-11-28
ZA201304014B (en) 2017-04-26
AU2011343368A1 (en) 2013-07-11
HRP20160606T1 (hr) 2016-07-01
CN103260642B (zh) 2018-03-16
IL226450A0 (en) 2013-07-31
WO2012080370A1 (en) 2012-06-21
BR112013014598A2 (pt) 2017-09-19
PT3023106T (pt) 2019-11-04
ES2574403T3 (es) 2016-06-17
BR112013014599A2 (pt) 2016-09-27
LT3023106T (lt) 2019-10-25
ES2748651T3 (es) 2020-03-17
PT2651436E (pt) 2016-06-08
US9730992B2 (en) 2017-08-15
SG190731A1 (en) 2013-07-31
MX2013006819A (es) 2013-08-26
EA027920B1 (ru) 2017-09-29
ES2567190T3 (es) 2016-04-20
PH12013501204A1 (en) 2013-07-29
DK2651436T3 (da) 2016-06-20
JP5951634B2 (ja) 2016-07-13
AR084285A1 (es) 2013-05-08
CN106822882A (zh) 2017-06-13
IL226448A (en) 2017-09-28
CY1122187T1 (el) 2020-11-25
HUE028452T2 (en) 2016-12-28
KR20130124525A (ko) 2013-11-14
EP3593813A1 (en) 2020-01-15
ZA201304015B (en) 2018-12-19
CA2819298A1 (en) 2012-06-21
CN103249431B (zh) 2016-11-02
EP2651437A1 (en) 2013-10-23
KR101951894B1 (ko) 2019-02-26
UY33802A (es) 2012-07-31
IL226448A0 (en) 2013-07-31
EP2651436B1 (en) 2016-03-30
UA110118C2 (uk) 2015-11-25
AU2011343368C1 (en) 2015-12-24
ME02380B (me) 2016-06-20
US10441648B2 (en) 2019-10-15
PL3023106T3 (pl) 2019-12-31
PH12013501203A1 (en) 2013-07-29
KR20140029376A (ko) 2014-03-10
EA201390630A1 (ru) 2013-12-30
US20130287809A1 (en) 2013-10-31
MX344706B (es) 2017-01-03
MY161412A (en) 2017-04-14
EP2651437B1 (en) 2016-02-10
DK3023106T3 (da) 2019-09-30
EP3023106A1 (en) 2016-05-25
SMT201600118B (it) 2016-07-01
EA027504B1 (ru) 2017-08-31
JP5951633B2 (ja) 2016-07-13
MX344280B (es) 2016-12-09
AU2011343367B2 (en) 2015-05-21
PL2651437T3 (pl) 2016-07-29
HRP20191843T1 (hr) 2019-12-27
SI2651436T1 (sl) 2016-07-29
US20160220656A1 (en) 2016-08-04
SG190937A1 (en) 2013-07-31
TW201305192A (zh) 2013-02-01
CO6751287A2 (es) 2013-09-16
EP2651436A1 (en) 2013-10-23

Similar Documents

Publication Publication Date Title
UA110806C2 (uk) Мікобактеріальна антигенна композиція
PH12012500849A1 (en) Mycobacterial vaccines
CY1120413T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
NZ585777A (en) Compositions and methods of enhancing immune responses to eimeria
NZ595792A (en) Antibodies specific to cadherin-17
EA201000327A1 (ru) Белок
CY1117963T1 (el) Αντισωματα που προσδενουν τα il-17a και il-17f
EA201391240A1 (ru) Слитые белки и комбинированные вакцины, содержащие белок е и пилин а haemophilus influenza
ES2585328T3 (es) Variantes no lipidadas de antígenos ORF2086 de Neisseria meningitidis
MX357505B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
RU2017104529A (ru) Композиции neisseria meningitidis и способы их применения
NZ599059A (en) Pcsk9 vaccine
CY1119916T1 (el) Ανοσογονικη συνθεση
MX340014B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340015B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX342291B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
EA201390820A1 (ru) Слитый белок против рака
UA107330C2 (uk) Туберкульозний білок rv3616c та його застосування
CY1118856T1 (el) Εμβολιο pcsk9
EA201692279A1 (ru) Способ уменьшения иммуногенности белка и пептида
AR128395A2 (es) Péptidos novedosos capaces de inducir la formación de anticuerpos contra pcsk9
BR112016016103A2 (pt) Composição de antígenos micobacterianos
NZ596501A (en) Casb7439 constructs
MX393714B (es) Anticuerpo para sesgar proporciones de sexos y metodos de uso del mismo.